Loading viewer...
investor_presentation
Format: PDF investor_presentation
Second Quarter CY2019 Supplemental Financial Information August 5, 2019
Second Quarter CY2019
Supplemental Financial Information
August 5, 2019KLA Non -Confidential | Unrestricted
2Q2-19 Key Financials
Total Company Shipments $1.354B
Semi Process Control Shipments $1.082B
Total Company Revenues $1.258B
GAAP Net Income $218M
GAAP Diluted EPS $1.35
Non-GAAP Net Income* $289M
Non-GAAP Diluted EPS* $1.78
*See appendix for GAAP to Non -GAAP reconciliationKLA Non -Confidential | Unrestricted
3Q2-19 Segment Information
Semiconductor Process Control $1.003B
Specialty Semiconductor Process $67M
PCB, Display and Component Inspection $185M
Total Revenue for Reportable Segments $1.258B*
*Figure may not sum due to roundingKLA Non -Confidential | Unrestricted
Cash and Investments $2.69B $1.90B $1.74B
Accounts Receivable, Net $658M $958M $990M
Net DSO (Shipment)* 55 days 76 days 67 days
Inventories $1.01B $1.32B $1.26B
Inventory Turns* 1.6x 1.7x 1.8x
Net Cash From Operating Activities $282M $164M $325M
Capital Expenditures, Net $26M $26M $55M
Free Cash Flow* $256M $138M $270M
Dividends Paid $115M $114M $121MQ2-19 Balance Sheet and Cash Flow Summary
*DSO = Current Net AR/ (Current Quarter Shipments / 91), Inventory Turns = Cost of Goods Sold/ Average Inventory, Free Cash F low= Net Cash Provided by Operating Activities –Net Capital Expenditures. Numbers have been
rounded KLA Non -Confidential | Unrestricted
5Q2-19 Revenue and Shipments Distribution
Preview truncated — download the full document for the complete content.
29 Pages
KLA Corporation Investor Presentation — April 2022
investor_presentationinvestor_presentation
24 Pages
KLA Corporation Investor Presentation — April 2024
investor_presentationinvestor_presentation
18 Pages
investor_presentation
37 Pages
Teck Resources Limited
Karyopharm Therapeutics Investor Presentation — December 2021
investor_presentationinvestor_presentation
139 Pages
Karyopharm Therapeutics Inc.